387 related articles for article (PubMed ID: 12897145)
1. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.
Romieu-Mourez R; Kim DW; Shin SM; Demicco EG; Landesman-Bollag E; Seldin DC; Cardiff RD; Sonenshein GE
Mol Cell Biol; 2003 Aug; 23(16):5738-54. PubMed ID: 12897145
[TBL] [Abstract][Full Text] [Related]
2. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland.
Demicco EG; Kavanagh KT; Romieu-Mourez R; Wang X; Shin SR; Landesman-Bollag E; Seldin DC; Sonenshein GE
Mol Cell Biol; 2005 Nov; 25(22):10136-47. PubMed ID: 16260626
[TBL] [Abstract][Full Text] [Related]
3. 7,12-dimethylbenz(a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-kappaB.
Shin SR; Sánchez-Velar N; Sherr DH; Sonenshein GE
Cancer Res; 2006 Mar; 66(5):2570-5. PubMed ID: 16510574
[TBL] [Abstract][Full Text] [Related]
4. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells.
Eddy SF; Guo S; Demicco EG; Romieu-Mourez R; Landesman-Bollag E; Seldin DC; Sonenshein GE
Cancer Res; 2005 Dec; 65(24):11375-83. PubMed ID: 16357145
[TBL] [Abstract][Full Text] [Related]
5. Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis.
Bagheri-Yarmand R; Talukder AH; Wang RA; Vadlamudi RK; Kumar R
Development; 2004 Jul; 131(14):3469-79. PubMed ID: 15226262
[TBL] [Abstract][Full Text] [Related]
6. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1.
Rocha S; Martin AM; Meek DW; Perkins ND
Mol Cell Biol; 2003 Jul; 23(13):4713-27. PubMed ID: 12808109
[TBL] [Abstract][Full Text] [Related]
7. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
Sovak MA; Bellas RE; Kim DW; Zanieski GJ; Rogers AE; Traish AM; Sonenshein GE
J Clin Invest; 1997 Dec; 100(12):2952-60. PubMed ID: 9399940
[TBL] [Abstract][Full Text] [Related]
8. NFkappaB1/p50 is not required for tumor necrosis factor-stimulated growth of primary mammary epithelial cells: implications for NFkappaB2/p52 and RelB.
Zhang J; Warren MA; Shoemaker SF; Ip MM
Endocrinology; 2007 Jan; 148(1):268-78. PubMed ID: 17008396
[TBL] [Abstract][Full Text] [Related]
9. beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland.
Michaelson JS; Leder P
Oncogene; 2001 Aug; 20(37):5093-9. PubMed ID: 11526497
[TBL] [Abstract][Full Text] [Related]
10. [Expression of NF-kappa B in human bladder cancer and its clinical significance].
Xie DH; Tang XD; Xia SJ; Tan JM; Wang XH; Cai Y
Ai Zheng; 2002 Jun; 21(6):663-7. PubMed ID: 12452071
[TBL] [Abstract][Full Text] [Related]
11. PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.
Belguise K; Sonenshein GE
J Clin Invest; 2007 Dec; 117(12):4009-21. PubMed ID: 18037997
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.
Rayet B; Fan Y; Gélinas C
Mol Cell Biol; 2003 Mar; 23(5):1520-33. PubMed ID: 12588973
[TBL] [Abstract][Full Text] [Related]
13. In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53.
Hosokawa Y; Papanikolaou A; Cardiff RD; Yoshimoto K; Bernstein M; Wang TC; Schmidt EV; Arnold A
Transgenic Res; 2001 Oct; 10(5):471-8. PubMed ID: 11708657
[TBL] [Abstract][Full Text] [Related]
14. The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.
Hunter JE; Butterworth JA; Zhao B; Sellier H; Campbell KJ; Thomas HD; Bacon CM; Cockell SJ; Gewurz BE; Perkins ND
Oncogene; 2016 Jun; 35(26):3476-84. PubMed ID: 26522720
[TBL] [Abstract][Full Text] [Related]
15. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
Fan Y; Rayet B; Gélinas C
Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the human P-selectin promoter by Bcl-3 and specific homodimeric members of the NF-kappa B/Rel family.
Pan J; McEver RP
J Biol Chem; 1995 Sep; 270(39):23077-83. PubMed ID: 7559449
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E
BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875
[TBL] [Abstract][Full Text] [Related]
18. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.
Cogswell PC; Guttridge DC; Funkhouser WK; Baldwin AS
Oncogene; 2000 Feb; 19(9):1123-31. PubMed ID: 10713699
[TBL] [Abstract][Full Text] [Related]
19. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.
Wang X; Belguise K; Kersual N; Kirsch KH; Mineva ND; Galtier F; Chalbos D; Sonenshein GE
Nat Cell Biol; 2007 Apr; 9(4):470-8. PubMed ID: 17369819
[TBL] [Abstract][Full Text] [Related]
20. RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members.
Jiang HY; Petrovas C; Sonenshein GE
J Virol; 2002 Jun; 76(11):5737-47. PubMed ID: 11992002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
